Wyeth’s Xyntha (antihemophilic factor VIII [recombinant]) is now available for both the control and prevention of bleeding episodes and surgical prophylaxis in patients with hemophilia A. Xyntha is plasma- and albumin-free and will replace Wyeth’s other recombinant antihemophilic factor VIII product, ReFacto, which will be discontinued as of May 31, 2009.

For more information call (800) 934-5556 or visit www.xyntha.com.